Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Northwest BiotherapeuticsNWBO +5.84%11 3-Year EBITDA Growth Rate is 29.20% as of Jun. 2026, which is 8% below its 10-year median of 31.60. GuruFocus rates NWBO with a GF Score™ of 11/100. The stock has 6 warning signs investors should review. Among 1,127 Biotechnology companies, Northwest Biotherapeutics ranks better than 65.84% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 29.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Northwest Biotherapeutics was 66.00% per year. The lowest was -44.20% per year. And the median was 31.60% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Northwest Biotherapeutics 3-Year EBITDA Growth Rate Related Terms
NWBO vs PRQR, IMRX, VNDA: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Northwest Biotherapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Northwest Biotherapeutics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Northwest Biotherapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Northwest Biotherapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 29.20% mean?
Northwest Biotherapeutics (NWBO) has a 3-Year EBITDA Growth Rate of 29.20% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Northwest Biotherapeutics and its competitors. This is near median its historical median of 31.60. According to the industry distribution chart, Northwest Biotherapeutics ranks #385 out of 1127 companies in the Biotechnology industry, placing it in the top 34.2%.
Is Northwest Biotherapeutics' 3-Year EBITDA Growth Rate too high?
Northwest Biotherapeutics' current 3-Year EBITDA Growth Rate of 29.20% is near median its 10-year median of 31.60. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Northwest Biotherapeutics' value of 29.20% is 96% above this industry median. Based on the distribution chart, Northwest Biotherapeutics ranks #385 out of 1127 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Northwest Biotherapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Northwest Biotherapeutics' 3-Year EBITDA Growth Rate compare to PRQR and IMRX?
According to the Biotechnology industry distribution chart, Northwest Biotherapeutics ranks #385 out of 1127 companies for 3-Year EBITDA Growth Rate. This puts Northwest Biotherapeutics in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.90. Northwest Biotherapeutics' value of 29.20% is 96% above this benchmark. While the company's 10-year median is 31.60 vs. the industry median of 14.90, Northwest Biotherapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Northwest Biotherapeutics's current 3-Year EBITDA Growth Rate of 29.20% is 96% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Northwest Biotherapeutics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Northwest Biotherapeutics's current 3-Year EBITDA Growth Rate is 29.20%, which is near median its own 10-year median of 31.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Northwest Biotherapeutics stock overvalued right now?
Northwest Biotherapeutics (NWBO) has a current 3-Year EBITDA Growth Rate of 29.20%. The current 3-Year EBITDA Growth Rate is 29.20%, which is near median its 10-year median of 31.60 and 96% above the Biotechnology industry median of 14.90. Northwest Biotherapeutics' overall GF Score™ is 11/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Northwest Biotherapeutics (NWBO), the current 3-Year EBITDA Growth Rate is 29.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Northwest Biotherapeutics Inc a biotechnology company focused on developing personalized immune therapies for cancer. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S Food and Drug Administration.
11GF Score
Get the complete analysis for NWBO
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NWBO has been successfully added to your 
